Tempest Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for TPST, updated each market day.
TPST AI Sentiment
AI predicts Tempest Therapeutics, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: Sept. 21, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Tempest Therapeutics, Inc. Common Stock
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Sector
Exchange
Market Cap
$14,803,091
Cap Tier
Employees
4
Headquarters
BRISBANE, CA
Listed Since
June 28, 2021
Website
TPST Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TPST Volatility
Tempest Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
